LIVIVO - Search results -

Search results

Result 1 - 10 of total 30

Book: Lupus erythematosus

Schur, Peter H. / Massarotti, Elena M.

clinical evaluation and treatment

2012

Author's details	Peter H. Schur ; Elena M. Massarotti ed
Keywords	Systemic lupus erythematosus ; Systemic lupus erythematosus--Diagnosis ; Systemic lupus erythematosus--Treatment
Language	English
Size	XI, 260 S. : Ill., graph. Darst., 24 cm
Publisher	Springer
Publishing place	New York u.a.
Publishing country	United States
Document type	Book
HBZ-ID	HT017356035
ISBN	978-1-4614-1188-8 ; 1-4614-1188-2 ; 9781461411895 ; 1461411890
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2012 A 3379	order for loan	Magazin

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis.

Massarotti, Elena M

Clinical therapeutics

2008 Volume 30, Issue 3, Page(s) 429–442

Abstract: Background: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation, which if left untreated leads to progressive disability and joint destruction. A combination of antiinflammatory agents, steroids, disease- ... ...

Abstract	Background: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation, which if left untreated leads to progressive disability and joint destruction. A combination of antiinflammatory agents, steroids, disease-modifying antirheumatic drugs, and biological agents are used to treat RA. Beyond the use of conventional measures of disease activity, such as American College of Rheumatology (ACR) response rates, the importance of patient-reported outcomes (PROs) in assessing therapeutic benefits is gaining increasing emphasis in clinical trials of RA and other chronic illnesses. Clinical trials testing new RA therapeutics generally include health-related quality of life (HRQoL) measures and assessments of function and disability. Abatacept, a costimulation modulator that selectively targets the activation of T cells and downregulates the immune response, has been approved by the US Food and Drug Administration for the treatment of RA, with or without methotrexate. Objective: The aim of this review was to summarize the clinical outcomes and PROs in published trials of abatacept. Methods: A literature search was performed using the MEDLINE, EMBASE, and BIOSIS databases (restricted to articles posted between January 2000 and September 2007) with the search terms CTLA-4Ig, abatacept, and Orencia to identify published trials of abatacept. Primary clinical trial publications in patients with RA were selected. The ACR response and PROs data presented in the identified publications are summarized in this review. Results: Our search identified 6 studies that met our selection criteria, which included 1 Phase IIa study, 2 Phase IIb studies, and 3 Phase III studies. The Phase IIa study found that abatacept was more effective than placebo and that physical function improved in treated patients compared with placebo. The 2 Phase IIb studies in 339 patients with RA previously treated with methotrexate found statistically significant improvements in HRQoL with abatacept at 6 months and 1 year. Similar findings were noted in the published Phase III trials. Across clinical trials, abatacept has been associated with clinically meaningful and statistically significant improvements in conventional measures of disease activity, HRQoL, and physical function. Conclusions: These 6 published trials found that abatacept was associated with significant improvements in both conventional measures of disease activity and PROs. Continued assessment of these outcomes will be required to further support the findings of the Phase II and III abatacept clinical trial literature reviewed here.
MeSH term(s)	Abatacept ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Clinical Trials as Topic/statistics & numerical data ; Health Status ; Humans ; Immunoconjugates/therapeutic use ; Pilot Projects ; Quality of Life ; Treatment Outcome
Chemical Substances	Antirheumatic Agents ; Immunoconjugates ; Abatacept (7D0YB67S97)
Language	English
Publishing date	2008-03
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	603113-4
ISSN	1879-114X ; 0149-2918
ISSN (online)	1879-114X
ISSN	0149-2918
DOI	10.1016/j.clinthera.2008.03.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1435: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 404: Show issues

Order via subito

Details ▾

Article ; Online: The potential role of ‘non-rheumatic’ therapies in rheumatic disease.

Massarotti, Elena M / Solomon, Daniel H

Arthritis research & therapy

2013 Volume 15, Issue 6, Page(s) 124

Abstract: The relationship between inflammation and insulin resistance is complex and not fully understood. Patients with rheumatoid arthritis are at increased risk of mortality from cardiovascular disease, which is known to be associated with insulin resistance. ... ...

Abstract	The relationship between inflammation and insulin resistance is complex and not fully understood. Patients with rheumatoid arthritis are at increased risk of mortality from cardiovascular disease, which is known to be associated with insulin resistance. In the previous issue of Arthritis Research & Therapy, Ormseth and colleagues report the results of an 8-week trial of pioglitazone, an agent commonly used to treat type 2 diabetes mellitus, upon the DAS-28 (disease activity score using 28 joint counts). Modest improvements in the DAS-28 CRP (DAS-28 C-reactive protein) were shown, with no effect on DAS-28 ESR (DAS-28 erythrocyte sedimentation rate). Other variables that improved with pioglitazone were the CRP, IL-6, and patient-reported assessment of global health. The authors discuss the contribution of insulin resistance to the inflammation noted in rheumatoid arthritis.
MeSH term(s)	Arthritis, Rheumatoid/drug therapy ; Female ; Humans ; Male ; PPAR gamma/agonists ; Thiazolidinediones/therapeutic use
Chemical Substances	PPAR gamma ; Thiazolidinediones
Language	English
Publishing date	2013-10-23
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Comment
ZDB-ID	2107602-9
ISSN	1478-6362 ; 1478-6354
ISSN (online)	1478-6362
ISSN	1478-6354
DOI	10.1186/ar4371
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5490: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Editorial: Interferon-Targeted Therapy for Systemic Lupus Erythematosus: Are the Trials on Target?

Massarotti, Elena M / Allore, Heather G / Costenbader, Karen

Arthritis & rheumatology (Hoboken, N.J.)

2016 Volume 69, Issue 2, Page(s) 245–248

MeSH term(s)	Antibodies, Monoclonal ; Humans ; Interferon-alpha ; Lupus Erythematosus, Systemic
Chemical Substances	Antibodies, Monoclonal ; Interferon-alpha ; anifrolumab
Language	English
Publishing date	2016-11-16
Publishing country	United States
Document type	Editorial ; Comment
ZDB-ID	2756371-6
ISSN	2326-5205 ; 2326-5191
ISSN (online)	2326-5205
ISSN	2326-5191
DOI	10.1002/art.39985
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 24: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: The new ACR/EULAR remission criteria: rationale for developing new criteria for remission.

Bykerk, Vivian P / Massarotti, Elena M

Rheumatology (Oxford, England)

2012 Volume 51 Suppl 6, Page(s) vi16–20

Abstract: As more effective treatments for RA have become available, studies have demonstrated that in patients who attained remission, defined as a simplified disease activity index (SDAI) ≤3.3, not only disease activity but radiographic progression was reduced. ... ...

Abstract	As more effective treatments for RA have become available, studies have demonstrated that in patients who attained remission, defined as a simplified disease activity index (SDAI) ≤3.3, not only disease activity but radiographic progression was reduced. The feasibility and the benefit of attaining remission led to the development of the ACR/European League Against Rheumatism (EULAR) 2011 remission criteria. These criteria employ either a Boolean definition, including tender and swollen joint counts ≤1, and CRP ≤1 mg/dl, or an index-based definition, SDAI ≤3.3, in combination with patient-reported outcomes on a scale of 0-10. It is expected that the ACR/EULAR criteria will be used as secondary outcomes in clinical trials. Some questions about the implementation of the new criteria include the availability of CRP values, and the possibility that patient-reported outcomes may skew the outcome if patients cannot distinguish other musculoskeletal conditions from RA. Several issues require further study, including the role of imaging, fatigue and the impact of the involvement of joints other than the 28 counted in the ACR/EULAR criteria.
MeSH term(s)	Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/classification ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/physiopathology ; C-Reactive Protein/metabolism ; Disease Progression ; Europe ; Humans ; Joints/physiopathology ; Remission Induction ; Societies, Medical ; United States
Chemical Substances	Antirheumatic Agents ; C-Reactive Protein (9007-41-4)
Language	English
Publishing date	2012-12
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	1464822-2
ISSN	1462-0332 ; 1462-0324
ISSN (online)	1462-0332
ISSN	1462-0324
DOI	10.1093/rheumatology/kes281
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 240: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 497: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The new ACR/EULAR classification criteria for RA: how are the new criteria performing in the clinic?

Bykerk, Vivian P / Massarotti, Elena M

Rheumatology (Oxford, England)

2012 Volume 51 Suppl 6, Page(s) vi10–5

Abstract: The objective of the 2010 ACR/European League Against Rheumatism classification criteria for RA was to distinguish patients at high risk for developing persistent erosive and/or inflammatory disease from those with undifferentiated inflammatory arthritis. ...

Abstract	The objective of the 2010 ACR/European League Against Rheumatism classification criteria for RA was to distinguish patients at high risk for developing persistent erosive and/or inflammatory disease from those with undifferentiated inflammatory arthritis. These criteria were developed for use in clinical trials; in order to implement these criteria most effectively, they need to be validated in real-world settings. The 1987 criteria may have led to underdiagnosis in the case of patients with positive anti-citrullinated peptide antibody values but no evidence of radiographic progression of joint erosion, or overdiagnosis in the case of some patients with FM; similarly, the possibility that the 2010 criteria may result in overdiagnosis cannot be excluded. Prospective validation of the 2010 criteria has been carried out in several cohorts, with reported sensitivities ranging from 0.50 to 0.60 and specificities from 0.88 to 0.97. The sensitivity and specificity of the 2010 criteria were 0.74 and 0.66 when compared against the gold standard of needing MTX therapy in the opinion of experienced clinicians, and 0.69 and 0.72 against the standard of having persistent synovitis despite DMARDs after 1 year. Other comparisons have yielded similar sensitivities and specificities, ranging up to 0.85 for the gold standard of needing MTX therapy. Questions remain concerning the utility of the 2010 criteria for non-arthritis health care practitioners, who may be less than expert in identifying swollen joints and may underestimate the number of joints affected by synovitis. US may be of value in the future, but its role remains to be validated.
MeSH term(s)	Arthritis, Rheumatoid/classification ; Arthritis, Rheumatoid/diagnosis ; Arthritis, Rheumatoid/therapy ; Biological Therapy ; Disease Progression ; Europe ; Humans ; Practice Patterns, Physicians'/trends ; Sensitivity and Specificity ; Societies, Medical ; United States
Language	English
Publishing date	2012-12
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	1464822-2
ISSN	1462-0332 ; 1462-0324
ISSN (online)	1462-0332
ISSN	1462-0324
DOI	10.1093/rheumatology/kes280
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 240: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 497: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book: Lupus erythematosus

Schur, Peter H / Massarotti, Elena M

clinical evaluation and treatment

2012

Author's details	Peter H. Schur, Elena M. Massarotti, editors
MeSH term(s)	Lupus Erythematosus, Systemic/diagnosis ; Lupus Erythematosus, Systemic/therapy ; Lupus Erythematosus, Systemic/complications ; Comorbidity
Language	English
Size	xi, 260 p. :, ill.
Publisher	Springer
Publishing place	New York
Document type	Book
ISBN	9781461411888 ; 9781461411895 ; 1461411882 ; 1461411890
Database	Catalogue of the US National Library of Medicine (NLM)

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: To what extent can preventive treatments prevent damage from systemic lupus erythematosus?

Massarotti, Elena M / Schur, Peter H

Current rheumatology reports

2011 Volume 13, Issue 4, Page(s) 317–323

Abstract: Managing lupus patients traditionally involves treating manifestations of active disease with the most effective and least toxic therapies so that "damage" from ongoing disease or treatments can be minimized. Damage in clinical epidemiologic studies is ... ...

Abstract	Managing lupus patients traditionally involves treating manifestations of active disease with the most effective and least toxic therapies so that "damage" from ongoing disease or treatments can be minimized. Damage in clinical epidemiologic studies is usually defined by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, a validated, organ-specific assessment tool. This review summarizes recent developments regarding organ-specific manifestations and lupus-related damage and their prevention.
MeSH term(s)	Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/physiopathology ; Disability Evaluation ; Endocrine System Diseases/epidemiology ; Endocrine System Diseases/physiopathology ; Gastrointestinal Diseases/epidemiology ; Gastrointestinal Diseases/physiopathology ; Glucocorticoids/therapeutic use ; Health Status Indicators ; Humans ; Kidney Diseases/epidemiology ; Kidney Diseases/physiopathology ; Lung Diseases/epidemiology ; Lung Diseases/physiopathology ; Lupus Erythematosus, Systemic/drug therapy ; Lupus Erythematosus, Systemic/epidemiology ; Lupus Erythematosus, Systemic/physiopathology ; Lupus Vasculitis, Central Nervous System/complications ; Lupus Vasculitis, Central Nervous System/epidemiology ; Morbidity ; Severity of Illness Index ; Skin Diseases/epidemiology ; Skin Diseases/physiopathology
Chemical Substances	Glucocorticoids
Language	English
Publishing date	2011-05-20
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2057357-1
ISSN	1534-6307 ; 1523-3774
ISSN (online)	1534-6307
ISSN	1523-3774
DOI	10.1007/s11926-011-0188-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5531: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Lyme arthritis.

Massarotti, Elena M

The Medical clinics of North America

2002 Volume 86, Issue 2, Page(s) 297–309

Abstract: Infection with B. burgdorferi can cause a large joint inflammatory arthritis in patients who have not been treated for early Lyme disease; the knee is the most common joint affected. The diagnosis depends on a history of known exposure to the spirochete, ...

Abstract	Infection with B. burgdorferi can cause a large joint inflammatory arthritis in patients who have not been treated for early Lyme disease; the knee is the most common joint affected. The diagnosis depends on a history of known exposure to the spirochete, characteristic clinical features, and serologic studies (ELISA and Western blot) confirming exposure to the spirochete. In most patients, antibiotic therapy is curative, but in a smaller percentage of patients, the presence of the HLA-DR beta 1*0401 haplotype can trigger treatment-resistant arthritis, in which antibiotic therapy is ineffective; in these instances, remittive agents, such as hydroxychloroquine and methotrexate, are indicated. Arthroscopic synovectomy may be considered when antibiotic therapy is not curative. Fibromyalgia can follow infection with B. burgdorferi but is unresponsive to antibiotic therapy; it is treated with tricyclic antidepressants and an exercise program. Lyme arthritis is the only chronic inflammatory arthritis in which the specific cause is known and can be cured. As such, it serves as an excellent model with which to study the pathogenesis of more common inflammatory arthritides, such as rheumatoid arthritis.
MeSH term(s)	Adult ; Anti-Bacterial Agents/therapeutic use ; Arthritis, Infectious/complications ; Arthritis, Infectious/diagnosis ; Arthritis, Infectious/drug therapy ; Arthritis, Infectious/microbiology ; Borrelia burgdorferi/isolation & purification ; Diagnosis, Differential ; Female ; Fibromyalgia/microbiology ; Humans ; Lyme Disease/complications ; Lyme Disease/diagnosis ; Lyme Disease/drug therapy ; Male ; Middle Aged
Chemical Substances	Anti-Bacterial Agents
Language	English
Publishing date	2002-03
Publishing country	United States
Document type	Case Reports ; Journal Article ; Review
ZDB-ID	215710-x
ISSN	1557-9859 ; 0025-7125
ISSN (online)	1557-9859
ISSN	0025-7125
DOI	10.1016/s0025-7125(03)00088-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.158: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus.

Ramsey-Goldman, Rosalind / Alexander, Roberta Vezza / Conklin, John / Arriens, Cristina / Narain, Sonali / Massarotti, Elena M / Wallace, Daniel J / Collins, Christopher E / Saxena, Amit / Putterman, Chaim / Brady, Kelley / Kalunian, Kenneth C / Weinstein, Arthur

ACR open rheumatology

2021 Volume 3, Issue 2, Page(s) 116–123

Abstract: Objective: To evaluate the usefulness of biomarkers to predict the evolution of patients suspected of systemic lupus erythematosus (SLE), designated as probable SLE (pSLE), into classifiable SLE according to the American College of Rheumatology (ACR) ... ...

Abstract	Objective: To evaluate the usefulness of biomarkers to predict the evolution of patients suspected of systemic lupus erythematosus (SLE), designated as probable SLE (pSLE), into classifiable SLE according to the American College of Rheumatology (ACR) classification criteria. Methods: Patients suspected of SLE were enrolled by lupus experts if they fulfilled three ACR criteria for SLE and were followed for approximately 1-3 years to evaluate transition into ACR-classifiable SLE. Individual cell-bound complement activation products (CB-CAPs), serum complement proteins (C3 and C4), and autoantibodies were measured by flow cytometry, turbidimetry, and enzyme-linked immunosorbent assay, respectively. Blood levels of hydroxychloroquine (HCQ) were measured by mass spectrometry. A multianalyte assay panel (MAP), which includes CB-CAPs, was also evaluated. A MAP of greater than 0.8 reflected the optimal cutoff for transition to SLE. Time to fulfillment of ACR criteria was evaluated by Kaplan-Meier analysis and Cox proportional hazards model. Results: Of the 92 patients with pSLE enrolled, 74 had one or two follow-up visits 9-35 months after enrollment for a total of 128 follow-up visits. Overall, 28 patients with pSLE (30.4%) transitioned to ACR-classifiable SLE, including 16 (57%) in the first year and 12 (43%) afterwards. A MAP score of greater than 0.8 at enrollment predicted transition to classifiable SLE during the follow-up period (hazard ratio = 2.72; P = 0.012), whereas individual biomarkers or fulfillment of Systemic Lupus International Collaborating Clinics criteria did not. HCQ therapy was not associated with the prevention of transition to SLE. Conclusion: Approximately one-third of patients with pSLE transitioned within the study period. MAP of greater than 0.8 predicted disease evolution into classifiable SLE.
Language	English
Publishing date	2021-02-04
Publishing country	United States
Document type	Journal Article
ISSN	2578-5745
ISSN (online)	2578-5745
DOI	10.1002/acr2.11219
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top

Your last searches

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED